Newborn concurrent hearing and genetic screening for hearing impairment: A systematic review and meta‑analysis
Experimental and Therapeutic Medicine · 16.07.2024 · 28 (3)
DOI: 10.3892/etm.2024.12654 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 16.07.2024. Verfasst von Ke Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Mianyang Maternity and Child Healthcare Hospital, Mianyang, Sichuan 621000, P.R. China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hearing loss is the most prevalent neurosensory disorder in humans, with significant implications for language, social and cognitive development if not diagnosed and treated early. The present systematic review and meta-analysis aimed to determine the rate of hearing screening pass and genetic screening failure [universal newborn hearing screening (UNHS) pass/genetic failure] and to investigate the advantages of combining newborn hearing and genetic screening for newborn hearing impairment. The PubMed, Embase and Cochrane databases were searched from inception to September 2023 to identify studies reporting the combination of neonatal hearing screening with genetic screening. Duplicate literature, unpublished literature, studies with incomplete data, animal experiments, literature reviews and systematic studies were excluded. All the data were processed by STATA15.1 statistical software. A total of nine cross-sectional studies were included in this meta-analysis. The sample sizes ranged from 1,716 to 180,469, and there were a total of 377,688 participants. The pooled results revealed that the prevalence of passing the UNHS while failing genetic screening was 0.31% (95% CI, 0.22-0.41%). The prevalence of UNHS pass and gap junction protein beta 2 and solute carrier family 26 member 4 variant screen failure was 0.01% (95% CI, 0.00-0.02%) and 0.00% (95% CI, 0.00%), respectively, while the prevalence of mitochondrially encoded 12S RRNA variant screening failure and UNHS pass was 0.21% (95% CI, 0.18-0.26%). Combined screening has a significant advantage over pure hearing screening, especially in terms of identifying newborns with mitochondrial gene mutations that render them sensitive to certain medications. In clinical practice, decision-makers can consider practical circumstances and leverage the benefits of combined newborn hearing and genetic screening for early diagnosis, early counseling, and early intervention in patients with hearing loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Mianyang Maternity and Child Healthcare Hospital, Mianyang, Sichuan 621000, P.R. China.
Zitieren
APA
Pan, K., Shang, Z., Liu, J., Wen, Y., Luo, J., Zou, D., Wang, A., Li, T., Liao, L., & Xie, P. (2024). Newborn concurrent hearing and genetic screening for hearing impairment: A systematic review and meta‑analysis. Experimental and Therapeutic Medicine, 28(3). https://doi.org/10.3892/etm.2024.12654
Vancouver
Pan K, Shang Z, Liu J, Wen Y, Luo J, Zou D, et al. Newborn concurrent hearing and genetic screening for hearing impairment: A systematic review and meta‑analysis. Experimental and Therapeutic Medicine. 2024;28(3). doi:10.3892/etm.2024.12654
BibTeX
@article{Pan2024,
author = {Pan, Ke and Shang, Zhirong and Liu, Jialin and Wen, Yidong and Luo, Jing and Zou, Dan and Wang, Aichun and Li, Tao and Liao, Lingyan and Xie, Pan},
title = {Newborn concurrent hearing and genetic screening for hearing impairment: A systematic review and meta‑analysis},
journal = {Experimental and Therapeutic Medicine},
year = {2024},
volume = {28},
number = {3},
doi = {10.3892/etm.2024.12654}
}
EUVIMED